Phase 2 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with liver cancer (hepatocellular carcinoma) that has been confirmed by a tissue or cell sample, and who have not yet received any treatment for it. A biopsy before treatment starts may not be needed if one has already been done, but diagnosis must be confirmed before treatment begins.
- People whose treating doctor considers them a suitable candidate for surgery.
- People who are willing and able to sign a dated consent form before joining the study.
- People who are in generally good physical condition, able to carry out normal daily activities with little or no limitation (rated 0 or 1 on a standard medical scale called the ECOG scale).
- People whose blood test results meet specific requirements, including healthy enough levels of white blood cells, red blood cells, platelets, liver function markers, and kidney function.
- People who are willing and able to use appropriate birth control during the study period.
- People who are willing and able to attend scheduled visits, follow the treatment plan, and complete required lab tests.
Who may not be able to join:
- People who have taken part in another clinical trial within the past 4 weeks.
- People who have fluid build-up in the abdomen (ascites), brain problems caused by liver failure (hepatic encephalopathy), or bleeding from enlarged veins in the food pipe or stomach.
- People who have serious other health conditions — such as heart disease, poorly controlled diabetes, or psychiatric disorders — that may affect their health outcomes.
- People who currently have or have previously been diagnosed with another type of cancer.
- People who are pregnant or breastfeeding.
- People who are unlikely to follow the study requirements reliably.
- People with poor blood clotting results, kidney failure requiring dialysis, severe hardening of the arteries, or blood pressure that is not well controlled (above 160/100 mmHg).
- People who are allergic to contrast agents (dyes used in medical scans).
- People who are taking medications or substances that could affect how the study drugs are absorbed or processed by the body.
- People who the trial investigators decide are not suitable for the trial for other reasons.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhenfeng Zhang, MD, PhD, Second Affiliated Hospital of Guangzhou Medical University
Phone: +862039195966
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
pCR rate for the study groups; mPR rate for the study groups
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.